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Follistatin is a functional antagonist of several members of the TGF-β family of secreted signaling 
factors, including myostatin, the most powerful inhibitor of muscle growth characterized to date. 
Myostatin inhibition offers a novel therapeutic strategy for muscular dystrophy by restoring skeletal 
muscle mass and suppressing the progression of muscle degeneration. To assess the potential 
benefits of follistatin in treating muscle degenerative diseases, we examined the expression of myo-
statin and follistatin in Mdx mice, a model for Duchenne muscular dystrophy, and in B10 mice as 
a control. Our results demonstrated a temporary and coincident expression of follistatin and myo-
statin in both mouse strains, but this expression was significantly higher in Mdx mice than in B10 
mice. The maximum expression of follistatin and myostatin in the presence of restoring necrotic 
muscle was detected 4 weeks after birth in Mdx mice. Interestingly, during the stage of complete 
regeneration, the absence of myostatin and follistatin proteins and a marked decrease in the 
expression of both genes were observed 9 weeks after birth in both mouse strains. These findings 
suggest that follistatin not only blocks myostatin but also allows other activators to function in 
muscle development, emphasizing that follistatin could be a very potent molecule in combating 
muscle loss during dystrophies and muscle ageing, disuse, or denervation.
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INTRODUCTION
Duchenne muscular dystrophy (DMD) is an eventually 
fatal disorder characterized by rapidly progressive muscle 
weakness and atrophy of muscle tissue. DMD is the most 
common form of muscular dystrophy. It is caused by a muta-
tion in the gene encoding dystrophin, an essential cell mem-
brane protein in muscle cells. There is no available cure at 
this time, although the activation of satellite cells could be a 
way to replace the damaged muscle tissue.
Muscle satellite cells are a distinct lineage of myogenic 
progenitors responsible for postnatal muscle growth and 
repair. Satellite cells are mitotically quiescent and express 
several myogenic markers. When stimulated by damage to 
the muscle, satellite cells are activated to reenter the cell 
cycle and express myogenic regulatory factors. The result-
ing myoblasts subsequently differentiate and fuse to form 
new, replacement myofibers (Bischoff, 1989).
The extracellular matrix (ECM) is a complex alloy of 
macromolecules, including collagen, proteoglycans, and gly-
coproteins. This matrix is not only the scaffold for cells in a 
given tissue but also serves as a reservoir for growth factors 
and modulates the cells’ activation status (Kresse and 
Schönherr, 2001), and is essential for normal myogenesis 
(Melo et al., 1996). Myostatin, a member of the transforming 
growth factor-beta (TGF-β) family, is a negative regulator of 
skeletal muscle growth (McPherron et al., 1997, Thomas et 
al., 2000) expressed predominantly in muscle and in the 
blood (McPherron et al., 1997; Zimmers et al., 2002). The 
dramatic effect of myostatin on postnatal growth is due to its 
negative regulation of satellite cell activation, proliferation, 
and self-renewal (McCroskery et al., 2003), and also to its 
inhibition of myoblast proliferation and differentiation 
(Thomas et al., 2000; Langley et al., 2002). Interestingly, 
inhibition of myostatin activity is capable of increasing 
muscle mass and strength in the postnatal period and even 
in adults. These observations suggest that targeting myosta-
tin would be suitable as a therapy for degenerative muscle 
diseases such as muscular dystrophy and cachexia, as well 
as for preventing muscle wasting due to aging (Whittemore 
et al, 2003; Grobet et al., 2003; Khurana and Davies, 2003). 
In fact, antibody-mediated myostatin blockage in Mdx mice, 
a model for Duchenne muscular dystrophy, was found to 
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ameliorate the pathophysiology and muscle weakness 
(Bogdanovich et al., 2002). Myostatin propeptide-mediated 
amelioration of the symptoms in Mdx mice has also been 
reported (Bogdanovich et al., 2005). Moreover, we have 
observed high levels of decorin expression during the regen-
erative stage in Mdx mice (Kado, unpublished), which 
enhanced the proliferation and differentiation of myogenic 
cells through suppressing myostatin activity (Kishioka et al., 
2008). Decorin has also been demonstrated to increase the 
activity of follistatin, a myostatin propeptide that blocks myo-
statin activity (Hill et al., 2002). Therefore, decorin may also 
have an indirect inhibitory effect on myostatin (Hill et al., 
2002).
Follistatin, a secreted glycoprotein, is a functional antag-
onist of several members of the TGF-β family, including 
myostatin. Myostatin inactivation by follistatin thus might 
offer a novel therapeutic strategy for muscular dystrophy by 
suppressing the progression of muscle degeneration and 
permitting skeletal muscle mass restoration. Benabdallah et 
al. (2008) reported that myostatin inhibition by follistatin in 
combination with myoblast transplantation is a promising 
novel therapeutic approach for treating muscle wasting in 
diseases such as Duchenne muscular dystrophy. To provide 
a background for understanding the function of myostatin 
and follistatin during muscle degeneration and regeneration 
in an animal model for DMD, we investigated the distribution 
and expression of these proteins in skeletal muscle of Mdx
mice, using B10 Scott Snells mice as a positive control.
MATERIALS AND METHODS
Specimens
Four groups of 10 Mdx male mice (C57BL/10ScSn) at the ages 
of 2, 3, 4, and 9 weeks, respectively, and four groups of 10 control 
mice (B10 Scott Snells) at the corresponding ages were used in the 
study. The mice were anesthetized with pentobarbital and sacrificed 
according to the Guidelines for Animal Experiments of Tokyo Dental 
College. The left tibialis anterior muscle (TA) from all mice was used 
for morphological examination and immunohistochemistry. The right 
TA muscle from all mice was used for western blotting, and the left 
for RT-PCR analysis.
Morphological examination
The TAs of Mdx and B10 mice were removed 2, 3, 4, and 9 
weeks after birth. The selected tissue was fixed in 4% paraformal-
dehide. The specimens were then dehydrated and embedded in 
paraffin by using a Tissue-Tek VIP M1500 rapid tissue processor 
(Sakura, Tokyo, Japan), and serial sections 4 μm thick were cut 
with an IVS-410 sliding microtome (Sakura, Tokyo, Japan). After the 
removal of paraffin, the samples were rinsed with water and stained 
with standard hematoxylin-eosin (H-E).
Immunohistochemistry
For dystrophin staining, antigen was retrieved in paraffin serial 
sections by autoclaving them at 121°C for 15 minutes. After non-
specific reactivity was blocked with DAKO protein for 10 min at 
room temperature, the sections were incubated overnight at 4°C 
with 2 μg/ml anti-dystrophin (Abcam ab15277). The distribution of 
the primary antibody was observed by subsequent application of a 
biotinylated anti-primary antibody for 30 minutes at room tempe-
rature (anti-rabbit Ig biotin, Dako E0432) and streptavidin-horserad-
ish peroxidase (Nichirei 426062) for 5 minutes at room temperature.
The immunostain was developed with a DAB/H2O2 solution 
(Histofine DAB Substrate Kit; Nichirei), and the sections were coun-
terstained with hematoxylin. As a negative control, sections were 
incubated with 2 μg/ml normal rabbit Ig (Dako X0936).
Western blotting analysis of myostatin and follistatin
Electrophoretically separated protein bands were analyzed by 
western blotting. Briefly, TAs from 2-, 3-, 4-, and 9-week-old mice 
were removed while the animals were anaesthetized. The muscles 
were weighed, frozen in liquid nitrogen, and stored at –80°C. 
Frozen muscles were minced with scissors in nine volumes of ice-
cold homogenization buffer. The minced muscle samples were then 
sonicated in a 250D Sonifier (Branson Ultrasonic, Danbury, CT, 
USA). The products were used for the preparation of washed myo-
fibers, which were then boiled in sample buffer for 2 min at a final 
protein concentration of 0.125 mg/ml. Total protein concentration 
was measured with the Bradford technique by using the Bio-Rad 
Protein Assay (Nippon Bio-Rad Laboratory) and a Gene Quantpro 
spectrophotometer (Amersham Pharmacia Biotech, Piscataway, 
NJ, USA). Western blotting analyses were performed to detect myo-
statin and follistatin. An equal amount of total protein (0.5 μg) for 
each group was separated on a 12.5% SDS-polyacrylamide gel and 
transferred to Immobilon P membrane (Millipore, Bedford, MA, 
USA). Membranes were blocked with 5% skim milk and incubated 
with each of the primary antibodies, anti-myostatin (1:1000, CMN 
AB3239) and anti-follistatin (1:500, GWB 18-003-44287), and det-
ected with a horseradish peroxidase-conjugated secondary anti-
rabbit/mouse IgG antibody by using a VECTASTAIN ABC Rabbit 
IgG Kit.
Reverse-transcription polymerase chain reaction analysis
From mice in each age group, the left TA muscle was removed 
and snap-frozen in liquid nitrogen. A QuickPrep Micro mRNA Puri-
fication Kit (Amersham Pharmacia Biotech UK, Buckinghamshire, 
UK) was used to extract mRNA, and a Ready-To-Go kit (Amersham 
Pharmacia Biotech UK) to prepare cDNA. After determination of the 
optimal PCR conditions for all primers, experiments were performed 
by using a LightCycler (Roche Diagnostics, Mannheim, Germany), 
which allows RNA quantification. Two primer sets (Table 1) were 
designed from specific segments of the entire DNA sequences of 
the myostatin and follistatin genes by using OLIGO 5 software (Bio-
gene, Huntingdon, UK). Experiments were performed according to 
the standard protocol for the LightCycler. Ready-to-use LC Fast-
Start DNA Master SYBR Green I (Roche) was used as a hot-start 
PCR reaction mixture for the LightCycler. A series of cDNA (4.0 ng/
μl) dilutions were prepared, including 1/105, 1/106, 1/107, 1/108, and 
1/109. PCR reactions for the diluted standards were conducted in 
20-μl volumes containing 10.2 μl of sterile water, 5 μl of diluted con-
trol cDNA product, 1.6 μl of 25 mM MgCl2, 2 μl of LC FastStart DNA 
Master SYBR Green I containing SYBR Green I (1/60,000 dilution), 
and 0.6 μl of each of the forward and reverse primers.
The experimental PCR reactions each contained 14.2 μl of 
sterile water, 1.6 μl of 25 mM MgCl, 2 μl of LC FastStart DNA 
Master SYBR Green I containing SYBR Green I (1/60,000 dilution), 
0.6 μl of forward primer (10 pmol/μl), 0.6 μl of reverse primer (10 
pmol/μl), and 1 μl of target DNA (5 pg/μl). The PCR mixtures (20 μl 
each) prepared for myostatin and follistatin were added to the glass 
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portion of the capillaries. PCR conditions were 95°C for 10 min, fol-
lowed by 45 cycles of 95°C for 10 s, 60°C for 10 s, and 72°C for 80 
s. Gene amplification was performed according to a melting pro-
gram of 70°C for 15 s, and fluorescence was continuously moni-
tored at a rate of 0.1°C/s.
The amount of final expression of each gene was obtained by 
dividing each gene expression level by 
that of the housekeeping gene GAPDH. 
Cycle threshold (Ct) values for the real-
time data for each gene were found to be: 
GAPDH, Ct=19; myostatin, Ct=23; follista-
tin, Ct=23. The primers used for GAPDH 
are given in Table 1.
Statistical analysis
Student’s t-test was used for statisti-




To observe histopathology, sam-
ples were stained with H-E (Fig. 1). 
At 2 weeks, Mdx mice showed nor-
mal skeletal muscle cells with the 
nuclei located on the periphery of 
each fiber. In contrast, large necrotic 
and fibrotic areas with many mac-
rophages were evident at 3-weeks in 
the muscular dystrophic animal 
model. Interestingly, many regenera-
tive skeletal muscle fibers with cen-
tral nuclei were observed at 4 weeks, 
and complete muscle regeneration 
was noticed at 9 weeks in Mdx mice, 
with an absence of macrophages. 
The positive control, B10 mice, 
showed normal skeletal muscle with-
out macrophages in all periods of 
time evaluated.
Immunohistochemistry of dystro-
phin in TA muscle
To clarify the absence of dystro-
phin in Mdx mice, we observed the 
immunolocalization of this protein 
(Fig. 2). We found immunoreaction to 
dystrophin to be absent or weak in 
the tibialis anterior muscle of Mdx
mice during the time course of evalu-
ation. In contrast, dystrophin was 
strongly expressed in the same 
muscle of B10 mice at 2, 3, 4, and 9 
weeks. Normal rabbit IgG used as a 
negative control in each group of the 
B10 and Mdx mice resulted in no 
immunoreaction.
Expression of myostatin and fol-
listatin proteins
Myostatin and follistatin were 
identified in the skeletal muscle of 
Mdx and B10 mice (Fig. 3). Myostatin and follistatin were 
detected in both animal strains at 2 weeks. Immunoreactive 
bands indicating these proteins were strongly expressed at 
3 and 4 weeks. However, myostatin and follistatin were not 
observed in Mdx or B10 mice at 9 weeks.
Fig. 1. Histology of the tibialis anterior muscle in Mdx and B10 mice; sections were stained 
with hematoxylin-eosin (H-E). At 2 weeks (2w) of age, normal muscle is evident in both animal 
strains; however, at 3 weeks (3w), extensive necrotic and fibrotic areas are evident in the Mdx
mice. At 4 weeks (4w), some regenerative muscle cells are evident in the Mdx mice. At 8 weeks 
(8w), dystrophic muscle has completely replaced regenerative muscle cells. Note the normal 
skeletal muscle in B10 mice at all ages. Scale bar, 50 μm.
Fig. 2. Immunohistochemical examination of dystrophin in the tibialis anterior muscle in Mdx
and B10 mice. No immunostaining for dystrophin is evident in Mdx mice at any of the ages 
examined. In contrast, dystrophin is strongly immunostained in B10 mice at all ages. Normal rab-
bit IgG used as negative control (NC) in both animal strains showed no specific immunoreaction. 
2w–9w, 2–9 weeks after birth. Scale bar, 50 μm.
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Quantitative analysis of the myostatin and follistatin 
genes
To determine whether myostatin or follistatin mRNA is 
expressed in the skeletal muscle of Mdx and B10 mice, total 
RNA was isolated from the TA and evaluated by RT-PCR 
analysis. Figs. 4 and 5 summarize the quantification of myo-
statin and follistatin mRNA in the skeletal muscle of Mdx
and B10 mice. Both genes began to show increased expres-
sion after 2 weeks, reaching maximum expression at 4 weeks 
and showing low expression at 9 weeks in both animal 
strains. Interestingly, Mdx mice showed significantly higher 
myostatin and follistatin expression than did B10 mice at 2, 
3, and 4 weeks after birth (P<0.05).
DISCUSSION
Duchenne muscular dystrophy (DMD) is an X-linked 
recessive muscle disease caused by the inability to synthe-
size dystrophin, which is involved with maintaining the integ-
rity of the sarcolemma. Muscle fibers undergo a process of 
degeneration and regeneration. Until now, there has been 
no known cure for DMD, and treatment has aimed at con-
trolling symptoms to maximize the quality of life; however, 
we believe that the activation of satellite cells could be a way 
to replace the damaged muscle tissue. Satellite cells repre-
sent a unique population of muscle precursor cells located 
between the basal lamina and sarcolemma of adult myo-
fibers (Bischoff and Heintz, 1994; Grounds et al., 1993). In 
response to several stimuli, quiescent satellite cells activate, 
proliferate, and differentiate to repair damaged skeletal 
muscle (Bischoff, 1989).
Mdx mice, which lack the muscle protein dystrophin and 
show histological lesions similar to those in human muscular 
dystrophy, are a suitable animal model for Duchenne mus-
cular dystrophy (DMD). To clarify the histology and the 
absence of dystrophin corresponding to DMD, H-E staining 
and immunolocalization of dystrophin were performed in 
Mdx mice. Histologically, Mdx mice showed large areas with 
degenerative, necrotic, and regenerative muscle fibers 
(Fig.1) but no immunoreaction to dystrophin (Fig. 2), corre-
sponding to DMD. In contrast, B10 mice showed normal 
skeletal muscle and immunolocalization of dystrophin. It has 
been reported that in somite-derived muscles of the extrem-
ities, muscle necrosis begins 2 weeks after birth, immedi-
ately followed by regeneration, and the majority of necrotic 
muscles are regenerated by 4 weeks after birth (Dangain 
and Vrbova, 1984; DiMario et al., 1991; Attal et al., 2000; 
Honda et al., 2007; Abe et al., 2007). We observed a similar 
pattern in Mdx mice, though over a different period of time, 
with complete muscle regeneration at 9 weeks.
Fig. 5. Expression of follistatin mRNA in the anterior tibialis muscle 
in Mdx and B10 mice. Numbers on the vertical axis represent the 
expression level relative to that of the housekeeping gene GAPDH. 
The pattern of follistatin mRNA expression is similar in Mdx and B10 
mice, with a gradual increase from 2 weeks after birth, maximum 
expression at 4 weeks, and a marked decrease at 9 weeks. Interest-
ingly, Mdx mice showed significantly higher follistatin expression 
than B10 mice at 2, 3, and 4 weeks after birth (*, P<0.05).
Fig. 3. Western blot analysis of myostatin and follistatin in the 
anterior tibialis muscle in Mdx and B10 mice. Note the similar pro-
tein expression in both animal strains, which show strong myostatin 
and follistatin expression at 3 and 4 weeks but lack both proteins at 
9 weeks. The numbers at the left indicate the molecular mass of the 
proteins in kiloDaltons. 2w–9w, 2–9 weeks after birth.
Fig. 4. Expression of myostatin mRNA in the tibialis anterior mus-
cle in Mdx and B10 mice. Numbers on the vertical axis represent the 
expression level relative to that of the housekeeping gene GAPDH. 
The pattern of myostatin mRNA expression is similar in Mdx and 
B10 mice, with a gradual increase from 2 weeks after birth, maxi-
mum expression at 4 weeks, and a marked decrease at 9 weeks. 
Interestingly, Mdx mice showed significantly higher myostatin 
expression than B10 mice at 2, 3, and 4 weeks after birth (*, P< 
0.05).
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Myostatin, a member of the transforming growth factor–
β family, is the most powerful inhibitor of muscle growth 
characterized to date. Mice lacking myostatin (Mstn –/–) 
exhibit a dramatic and widespread increase in muscle mass 
resulting from a combination of hyperplasia and hypertrophy 
(McPherron, 1997). In fact, Kirk et al. (2000) found an 
increase in myostatin in necrotic muscle tissue but dec-
reased expression in regenerative myogenic cells. We made 
similar observations in the current study. We observed 
strong expression of myostatin protein and a high level of 
myostatin mRNA in the presence of necrotic tissue forma-
tion after 3 weeks of birth. Interestingly, in both Mdx and 
B10 mice after 9 weeks of birth, we observed a complete 
regenerative muscle mass without evidence of myostatin. 
These findings raise the possibility that blocking myostatin 
activity may be an effective therapeutic strategy for increas-
ing muscle strength in patients with muscle degenerative 
diseases, including the muscular dystrophies.
Follistatin, a secreted glycoprotein under study due its 
role in the regulation of muscle growth in mice, is an anta-
gonist to myostatin and rescues muscle differentiation 
(Amthor et al., 2004). Although follistatin shows potent 
myostatin-inhibiting effects, it also acts as an effective 
inhibitor of activins (Nakatami et al., 2008, Tsuchida et al., 
2008). Because activins are involved in multiple functions in 
various organs, their blockage by follistatin would affect mul-
tiple tissues other than skeletal muscle (Nakatami et al., 
2008, Tsuchida et al., 2008). For this reason a myostatin 
inhibitor derived from follistatin was developed that does not 
affect activin signaling (Nakatami et al., 2008, Tsuchida et 
al., 2008).
In the present study, we examined the expression of 
myostatin and follistatin in Mdx mice, and in B10 mice as a 
control. We detected temporary and coincident expression 
of the follistatin and myostatin proteins in both groups (Fig. 
3). The time course of follistatin and myostatin gene expres-
sion pattern was similar in both groups, but significantly 
higher in Mdx mice than in B10 mice 2, 3, and 4 weeks after 
birth (Figs. 4, 5). Maximum follistatin and myostatin gene 
expression occurred at 4 weeks in the presence of restoring 
necrotic muscle. On the other hand, during the stage of 
complete regeneration, an absence of the myostatin and fol-
listatin proteins and a marked decrease in the expression of 
both genes were observed 9 weeks after birth in both mouse 
strains. Interestingly, the myostatin mRNA level significantly 
increases in C2C12 cells treated with rh-follistatin at an early 
stage, but then sharply decreases at a late stage (Kocamis 
et al., 2004). This suggests that the beneficial effect of fol-
listatin would occur in the presence of degenerative and 
necrotic muscle fibers.
We recently observed high levels of decorin expression 
during the regenerative stage of Mdx mice (Kado, unpub-
lished observations). Decorin, a small leucine-rich prot-
eoglycan gene family member composed of a core protein 
and a dermatan/chondroitin sulfate chain (Schönherr et al., 
1995) enhances the proliferation and differentiation of myo-
genic cells by suppressing myostatin activity (Kishioka et al., 
2008). Decorin has also been demonstrated to increase fol-
listatin activity (Hill et al., 2002). Therefore, we believe that 
follistatin not only blocks myostatin but also allows decorin 
and other activators of muscle development to function. 
Moreover, it is important to mention that the expression of 
both myostatin and follistatin could have been influenced by 
the presence of macrophages in Mdx mice, and by growing 
skeletal muscle in the positive control mice. Our results 
emphasize that follistatin could be a very potent molecule for 
combating muscle loss during dystrophies and muscle 
aging, disuse, or denervation.
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